{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-21-064319","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2021-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.817999+00:00","generated_at":"2026-06-28T02:24:16.849494+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Adial Pharmaceuticals appoints Cary Claiborne as COO effective Dec 6, 2021","bullets":["Cary Claiborne appointed COO; continues to serve on Board of Directors.","Employment agreement: $304,000 base salary, 25% target bonus, three-year term.","Awarded option to purchase 130,000 shares at $2.77, vesting monthly over 36 months.","Joseph Truluck resigns as COO but remains CFO of the company.","Press release issued December 8, 2021 announcing the appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-21-064319","json":"https://secwatch.observer/filing/0001213900-21-064319.json","markdown":"https://secwatch.observer/filing/0001213900-21-064319.md","text":"https://secwatch.observer/filing/0001213900-21-064319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021064319/0001213900-21-064319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021064319/ea151938-8k_adialpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:24:16.849494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3b808eab0","claim":"Cary Claiborne was appointed as Chief Operating Officer at ADIAL PHARMACEUTICALS, INC..","evidence_excerpt":"On December 6, 2021, Adial Pharmaceuticals, Inc. (the “Company”) appointed Cary Claiborne as the Company’s Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390021064319/0001213900-21-064319-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}